San Diego, CA--December 14, 2009--Mentor Capital, Inc.'s (Pink Sheets: MNTR) proprietary Cancer Immunotherapy Index has appreciated at a 100% annualized rate since its creation by Mentor Capital, July 10, 2009. In response to the resulting investor interest, Mentor Capital plans to initiate an actively managed Cancer Immunotherapy Index fund in January 2010. A significant majority of Mentor Capital cash proceeds that spring from its $140 Million in freely tradable warrants are targeted to be invested through the fund.

Investment across the Cancer Immunotherapy Index will broaden Mentor Capital's already significant immunotherapy investment interest in CI Index member Quantum Immunologics, Inc., a private company in FDA authorized breast cancer trials. Other Cancer Immunotherapy Index companies are: Dendreon (NASDAQ:DNDN), Oncothyreon (NASDAQ:ONTY), ImmunoCellular Therapeutics (OTCBB:IMUC), Antigenics (NASDAQ:AGEN), Biovest International (BVTI.PK), Celldex Therapeutics (NASDAQ:CLDX), Northwest Biotherapeutics (OTCBB:NWBO), CEL - SCI Corp. (AMEX:CVM) and Generex Biotechnology (NASDAQ:GNBT) as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express. As other companies are brought into the CI Index, Mentor Capital will take an investment position in them with specific weighting based on the evaluation of their medical promise.

$1.2 Million in initial seed funding for the CI Index will be provided approximately one-third each by Mentor Capital management, WellCap Partners who will administer the fund under Mentor Capital direction, and Mentor Capital warrant holders. To allow for the Mentor Capital warrant holder funding, their Mentor Capital Series C warrants are set to $0.65 and called by this notice, subject to redemption on February 1, 2010.

In cancer immunotherapy, instead of chemotherapy, surgeries and radiation, the body’s own immune system is triggered to attack cancer cells. The USA market addressed by the Cancer Immunotherapy Index companies is estimated at $45 Billion. The current combined market cap of the index component companies is $3.4 Billion.

Regular detail updates of the Cancer Immunotherapy Index and additional company information may be reviewed at www.MentorCapital.com.

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.

__________

Chet Billingsley is the CEO and Chairman of Mentor Capital, Inc. Mentor Capital, Inc. invests in leading-edge cancer companies across all companies in its proprietary Cancer Immunotherapy Index and seeks to overweight acquisition or stock purchase funding in those companies with the greatest promise.

Chet Billingsley, CEO

Mentor Capital, Inc.
P.O. Box 1709
Ramona, CA 92065
(760) 788-4700
(760) 788-2525 Fax

 ↑ Back to Top